Other important safety issues associated with natalizumab treatment, and information about the patient populations suitable for treatment, are fully described in the SmPC, and physicians should ensure that this guidance document is used together with the SmPC and Patient Information Leaflet.
Other risk minimisation materials include Treatment Initiation, Continuation and Discontinuation Forms, that discuss the risk of PML in these situations.